BXTAccelyon Blog

February 22, 2018

BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide and the sole distribution partner outside North America for the new PrecisionPoint™ Transperineal Access System, announces its availability to the Australian healthcare market. The new medical device, which has recently received TGA approval, offers urologists a safer and more accurate method to diagnose potential incidents of prostate cancer.

Please reload

  • Black Facebook Icon
  • Black Twitter Icon
  • Black LinkedIn Icon
  • Black YouTube Icon
Featured Posts

BXTAccelyon and Hitachi Medical Systems to support #TRexit

As the national campaign to eradicate traditional transrectal (TRUS) biopsies from the prost...

BXTAccelyon and Hitachi Medical Systems to support #TRexit